乌司替尼诱发水痘带状疱疹感染的病例报告

Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas
{"title":"乌司替尼诱发水痘带状疱疹感染的病例报告","authors":"Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas","doi":"10.36348/sjmps.2024.v10i07.011","DOIUrl":null,"url":null,"abstract":"Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.","PeriodicalId":508857,"journal":{"name":"Saudi Journal of Medical and Pharmaceutical Sciences","volume":" 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report on Ustekinumab-Induced Varicella Zoster Infection\",\"authors\":\"Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas\",\"doi\":\"10.36348/sjmps.2024.v10i07.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.\",\"PeriodicalId\":508857,\"journal\":{\"name\":\"Saudi Journal of Medical and Pharmaceutical Sciences\",\"volume\":\" 22\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Journal of Medical and Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36348/sjmps.2024.v10i07.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36348/sjmps.2024.v10i07.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

Ustekinumab 是一种人类单克隆抗体,通常用于治疗中度至重度斑块状银屑病、银屑病关节炎、中度至重度克罗恩病或中度至重度溃疡性结肠炎(炎症性肠病)。乌司替库单抗通过作为白细胞介素-12(IL12)和白细胞介素-23(IL23)的拮抗剂来介导机体的T细胞反应。使用 Ustekinumab 有可能导致严重感染或现有感染(细菌、霉菌、真菌、病毒)加重/复燃,尽管这种情况很少见。我们报告了一例 29 岁女性患者的病例,她在治疗克罗恩病时被处方 Ustekinumab。用药两剂后,她患上了水痘肺炎并伴有 ARDS,随后得到了控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Case Report on Ustekinumab-Induced Varicella Zoster Infection
Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信